Cargando…
Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
BACKGROUND: Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization be...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474769/ https://www.ncbi.nlm.nih.gov/pubmed/37658454 http://dx.doi.org/10.1186/s12985-023-02167-z |
_version_ | 1785100574580015104 |
---|---|
author | Kroidl, Inge Winter, Simon Rubio-Acero, Raquel Bakuli, Abhishek Geldmacher, Christof Eser, Tabea M. Déak, Flora Horn, Sacha Zielke, Anna Ahmed, Mohamed I. M. Diepers, Paulina Guggenbühl, Jessica Frese, Jonathan Bruger, Jan Puchinger, Kerstin Reich, Jakob Falk, Philine Markgraf, Alisa Fensterseifer, Heike Paunovic, Ivana Thomschke, Angelika Pritsch, Michael Riess, Friedrich Saathoff, Elmar Hoelscher, Michael Olbrich, Laura Castelletti, Noemi Wieser, Andreas |
author_facet | Kroidl, Inge Winter, Simon Rubio-Acero, Raquel Bakuli, Abhishek Geldmacher, Christof Eser, Tabea M. Déak, Flora Horn, Sacha Zielke, Anna Ahmed, Mohamed I. M. Diepers, Paulina Guggenbühl, Jessica Frese, Jonathan Bruger, Jan Puchinger, Kerstin Reich, Jakob Falk, Philine Markgraf, Alisa Fensterseifer, Heike Paunovic, Ivana Thomschke, Angelika Pritsch, Michael Riess, Friedrich Saathoff, Elmar Hoelscher, Michael Olbrich, Laura Castelletti, Noemi Wieser, Andreas |
author_sort | Kroidl, Inge |
collection | PubMed |
description | BACKGROUND: Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU). METHODS: To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay. RESULTS: In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43–51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly. CONCLUSION: The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02167-z. |
format | Online Article Text |
id | pubmed-10474769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104747692023-09-03 Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison Kroidl, Inge Winter, Simon Rubio-Acero, Raquel Bakuli, Abhishek Geldmacher, Christof Eser, Tabea M. Déak, Flora Horn, Sacha Zielke, Anna Ahmed, Mohamed I. M. Diepers, Paulina Guggenbühl, Jessica Frese, Jonathan Bruger, Jan Puchinger, Kerstin Reich, Jakob Falk, Philine Markgraf, Alisa Fensterseifer, Heike Paunovic, Ivana Thomschke, Angelika Pritsch, Michael Riess, Friedrich Saathoff, Elmar Hoelscher, Michael Olbrich, Laura Castelletti, Noemi Wieser, Andreas Virol J Research BACKGROUND: Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU). METHODS: To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay. RESULTS: In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43–51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly. CONCLUSION: The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02167-z. BioMed Central 2023-09-01 /pmc/articles/PMC10474769/ /pubmed/37658454 http://dx.doi.org/10.1186/s12985-023-02167-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kroidl, Inge Winter, Simon Rubio-Acero, Raquel Bakuli, Abhishek Geldmacher, Christof Eser, Tabea M. Déak, Flora Horn, Sacha Zielke, Anna Ahmed, Mohamed I. M. Diepers, Paulina Guggenbühl, Jessica Frese, Jonathan Bruger, Jan Puchinger, Kerstin Reich, Jakob Falk, Philine Markgraf, Alisa Fensterseifer, Heike Paunovic, Ivana Thomschke, Angelika Pritsch, Michael Riess, Friedrich Saathoff, Elmar Hoelscher, Michael Olbrich, Laura Castelletti, Noemi Wieser, Andreas Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison |
title | Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison |
title_full | Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison |
title_fullStr | Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison |
title_full_unstemmed | Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison |
title_short | Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison |
title_sort | studying temporal titre evolution of commercial sars-cov-2 assays reveals significant shortcomings of using bau standardization for comparison |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474769/ https://www.ncbi.nlm.nih.gov/pubmed/37658454 http://dx.doi.org/10.1186/s12985-023-02167-z |
work_keys_str_mv | AT kroidlinge studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT wintersimon studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT rubioaceroraquel studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT bakuliabhishek studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT geldmacherchristof studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT esertabeam studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT deakflora studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT hornsacha studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT zielkeanna studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT ahmedmohamedim studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT dieperspaulina studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT guggenbuhljessica studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT fresejonathan studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT brugerjan studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT puchingerkerstin studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT reichjakob studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT falkphiline studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT markgrafalisa studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT fensterseiferheike studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT paunovicivana studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT thomschkeangelika studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT pritschmichael studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT riessfriedrich studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT saathoffelmar studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT hoelschermichael studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT olbrichlaura studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT castellettinoemi studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT wieserandreas studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison AT studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison |